Humanized EL4-hCD20-LZ Reporter Tumor Cell Line

Reporter Immune Checkpoint Cell Lines

Design of the EL4-hCD20-LZ cell line

The EL-4 cell line was established from a C57BL/6 murine lymphoma. These cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.

We generated an EL4-hCD20-LZ clonal cell line expressing high levels of human CD20 (MS4A1 NCBI GeneID: 931), and an optimized dual fusion reporter luciferase-ZsGreen (LZ). EL4-hCD20-LZ cells form tumors in vivo when injected systemically. Luciferase-ZsGreen (LZ) control cells are available.



Request a quote here to get pricing, offers and EL4-CD20-LZ model information by phone or email.


EL4-hCD20-LZ features

  • Express a fully human CD20
  • Express a luciferase-ZsGreen (LZ) fusion reporter
  • Form tumors and impact survival upon systemic injection in fully immunocompetent mice
  • Luciferase from injected cells can be detected by in vivo imaging


EL4-hCD20-LZ validation*

EL4-hCD20-LZ_img01EL4-hCD20-LZ cells homogeneously express human CD20 in vitro

Expression analysis by flow cytometry. Human CD20 expression was assessed in EL4 parental cell line (left), human control cells – PBMC (center), and EL4-hCD20-LZ cell line (right).

EL4-hCD20-LZ_img02EL4-hCD20-LZ cells impair survival in systemic syngeneic model

Wild-type C57/Bl6 mice were injected (i.v.) with 2x104 EL4-hCD20-LZ cells (red) or EL4 parental cells (blue), or with PBS (dotted black). Survival was followed over 37 days.

* For more validation data please contact us.

Ready to be shipped to your lab

  • Biosafety level BSL1, according to Kerafast guidelines (parental cell line provider)
  • Studies can be carried out at your site or at your favorite CRO
  • Models provided with FTO on patent-protected technologies used for model generation

Are you looking for another target?
Please contact us.